World Alzheimer's Day 2025

This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by discussing the understudied impacts of the gut microbiome and chronic inflammation that may contribute to neurodegeneration.

This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by considering the role heavy metals such as lead, mercury, and cadmium can play in Alzheimer's Disease.

This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by identifying potential nutraceutical applications of bioactive compounds for prevention and treatment of Alzheimer's Disease.

This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by discussing the roles of Tau, glial, and amyloid (A) in Alzheimer's Disease development.

This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by exploring a novel area of research exploring the link between vascular disease and Alzheimer's Disease.

Purpose: Sarcopenia or age-associated muscle loss is common in patients with Alzheimer's disease (AD). We have previously demonstrated the contribution of a leaky gut to sarcopenia in AD. Here, we asked whether resistant exercise (RE) reduces the sarcopenia phenotype by repairing intestinal leakage in patients with AD.

The impact of Alzheimer's disease (AD) and its related dementias is rapidly expanding, and its mitigation remains an urgent social and technical challenge. To date there are no effective treatments or interventions for AD, but recent studies suggest that alcohol consumption is correlated with the risk of developing dementia. In this review, we synthesize data from preclinical, clinical, and epidemiological models to evaluate the combined role of alcohol consumption and serotonergic dysfunction in AD, underscoring the need for further research on this topic.

The study examined factors affecting the willingness of African-American and American Indian/Alaska Native communities to participate in Alzheimer's disease genetic and biomarker research, finding that these groups expressed less positive attitudes toward research compared to non-Hispanic White participants, which was related to their lower willingness to engage in preclinical Alzheimer's biomarker testing

The article discusses the potential of neuron-derived extracellular vesicles (NDEVs) as diagnostic biomarkers for Alzheimer's disease (AD). NDEVs carry pathological proteins like amyloid-? and Tau, and their levels in bodily fluids can distinguish AD patients from healthy controls and predict disease onset.

Evidence from preclinical research suggests that dysfunction in thyroid hormones may increase ?-amyloid levels and tau phosphorylation, 2 hallmark features of Alzheimer's Disease(AD). This study showed a strong association between hypothyroidism and AD mortality.

The article investigates the role of CD38, an enzyme implicated in neuroinflammation and cellular senescence, in the context of vascular dementia (VaD). It demonstrates that inhibiting CD38 can mitigate cerebrovascular endothelial cell dysfunction, blood-brain barrier disruption, neuroinflammation, and white matter damage, ultimately alleviating cognitive impairment in a mouse model of VaD. The findings suggest that targeting CD38 may offer a promising therapeutic strategy for addressing the vascular and neurological deficits associated with VaD

The article discusses the potential relationship between alcohol consumptiond the development of Alzheimer's disease (AD), highlighting the role of the serotonergic system as a potential mediator. It synthesizes data from preclinical, clinical, and epidemiological studies to explore how alcohol-induced changes in serotonin function, neuroinflammation, and proteostasis may contribute to the onset and progression of AD

This study identified over 2,000 proteins in cerebrospinal fluid that change at different stages before Alzheimer's symptoms appear, revealing key biological processes involved in the disease. Using machine learning, the researchers developed highly accurate models to predict Alzheimer's biomarker status, clinical diagnosis, and future disease progression.

This study identifies two CSF proteomic panels that accurately stage Alzheimer’s pathology, outperform current biomarkers, and predict dementia progression over 10 years, enhancing diagnosis and clinical trial stratification.

Real-world evidence can supplement clinical trial data to optimize Alzheimer’s disease care by aiding early patient identification and assessing drug effectiveness and safety in everyday use in diverse clinical settings/populations. This information helps inform clinical practice guidelines and supports the development of tools for timely diagnosis and personalized treatment strategies.

The article discusses the role of gut dysbiosis, bacterial amyloids, and metabolic diseases in the development and progression of Alzheimer's disease (AD). It highlights the bidirectional relationship between the gut microbiome, inflammation, and metabolic disorders, and how these interconnected pathways contribute to neurodegeneration. The review explores potential therapeutic strategies targeting the gut-brain-metabolic axis to mitigate AD progression.

This study provides evidence of distinct alterations in resting-state functional connectivity in individuals with amnestic mild cognitive impairment (aMCI) and late-life depression (LLD), underscoring region-specific vulnerabilities that may contribute to cognitive decline and depressive symptomatology in older adults.

This article systematically summarizes the neuroprotective effects and mechanisms of ginsenosides Rg1, Rb1, and rare ginsenosides against Parkinson's disease (PD) and Alzheimer's disease (AD). The key findings indicate that ginsenosides exert their beneficial effects by modulating various signaling pathways related to inflammation, oxidative stress, apoptosis, and autophagy.

The article explores the role of microglia and neuronal subpopulations in Alzheimer's disease (AD) progression. It reveals that the microglia subpopulation Mic_PTPRG communicates with specific excitatory (ExNeu_PRKN_VIRMA) and inhibitory (InNeu_PRKN_VIRMA) neuronal subpopulations, leading to the upregulation of VIRMA, which inhibits mitophagy and causes neuronal death.

This cross-sectional population-based study examined the relationship between statin use and anti-Alzheimer's disease (AD) drug prescription in patients over 70 years old with cardiovascular risk factors. The key findings were: 1) Patients using low-potency or hydrophilic statins had lower odds of anti-AD medication usage compared to high-potency or lipophilic statins, respectively; 2) Patients taking rosuvastatin or pitavastatin had lower odds of anti-AD medication usage than those consuming atorvastatin.

This study shows that the Cognitive Stimulation Therapy program can significantly improve general cognition, communication, and reduce depression in people living with dementia, regardless of the underlying pathology. However, the effects vary by dementia subtype, with some gains maintained long-term in vascular dementia (VaD) but not in Alzheimer, especially regarding narrative abilities and depressive symptoms, highlighting the importance of personalized approaches.

Report on a new smart delivery system designed to target and treat Alzheimer's disease more effectively, aiming to overcome the challenges of current treatments and offering a promising way to fight Alzheimer's more accurately and safely.

This article provides a comprehensive review of the use of graphene-based biosensing platforms for the early detection of Alzheimer's disease. It is found that graphene-based biosensors can detect Alzheimer's disease biomarkers at femtomolar concentrations, enabling early diagnosis before symptom onset. These sensors can also identify multiple biomarkers simultaneously in accessible biofluids like blood, saliva, and urine, enabling less invasive testing.

The article suggest that beta-amyloid protein (Aβ) has a significant indirect effect on neurogranin (Ng) through key synaptic mediators such as SYT1 and GAP43 during the preclinical stages of Alzheimer’s disease (AD). These findings highlight the crucial role of SYT1 and GAP43 in mediating beta-amyloid-induced synaptic dysfunction, offering potential early biomarkers and therapeutic targets for AD progression.

The article presents PI4AD, a computational medicine framework that integrates multi-omics data, systems biology, and artificial neural networks to prioritize therapeutic targets for Alzheimer's disease (AD). PI4AD recovers clinically validated targets like APP and ESR1, confirming its prioritization efficacy. The framework identifies Ras signaling as a central therapeutic hub, complementing traditional amyloid/tau-focused approaches. Crosstalk analysis reveals critical nodal genes (e.g., HRAS and MAPK1) and drug repurposing opportunities, bridging genetic insights with pathway-level biology.

This article provides a narrative review of the relationships between modifiable lifestyle factors and plasma biomarkers of Alzheimer's disease (AD). The key findings are that better nutrition, more physical activity, and good sleep quality are associated with more favorable plasma AD biomarker profiles, potentially reflecting less cerebral AD pathology.

This study investigated the prevalence and impact of auditory agnosia for environmental sounds in individuals with Alzheimer’s disease (AD), finding that over half exhibited signs of this central auditory dysfunction along with a high rate of unrecognized peripheral hearing loss. Although these factors appeared independent and showed limited direct effect on measured quality of life, possibly due to sheltered living environments and lack of patient awareness, they jointly contribute to daily functional decline, highlighting the importance of early hearing assessment and intervention in AD management.

This article describes the discovery and characterization of FJMU1887, a novel brain-penetrant small-molecule inhibitor of Galectin-3 (Gal-3) identified through an AI-driven drug discovery platform. FJMU1887 demonstrated potent anti-inflammatory effects, reduced Aβ pathology, and improved cognitive function in Alzheimer's disease mouse models, highlighting its therapeutic potential for the treatment of Alzheimer's disease.

The article estimates the value-based price of a blood test for Alzheimer's disease pathology, finding it would be $290-$1150 in primary care and $450-$1950 in specialty care, projecting substantial cost savings.

This article provides a bibliometric analysis of 545 linguistics research articles on dementia published between 1994 and 2023, highlighting key contributors, influential journals, and foundational references.

The TRAILBLAZER-ALZ 6 study found that a modified donanemab titration regimen significantly reduced ARIA-E frequency and severity compared to standard dosing, while maintaining similar amyloid reduction. Safety profiles were comparable between the two arms. The modified titration approach may help mitigate risks associated with amyloid-targeting therapies in early Alzheimer's disease.

Article discusses the relationship between hypertension and dementia, and the potential utility of antihypertensive medications in reducing the risk of cognitive decline and dementia. It concludes that mid-life hypertension is a risk factor for both vascular dementia and Alzheimer's disease, and that further research is needed to clarify the neuroprotective properties of different antihypertensive drug classes.

The review summarizes and discusses the potential role of psilocybin, a psychedelic compound, in altering mechanisms associated with major depression and neurodegenerative diseases. It examines the relationship between adult hippocampal neurogenesis, microglial activity, and their implications for the development of dementia, particularly in the context of major depression as a risk factor.

In the Han Chinese populations on the Mongolian Plateau, the MTHFR G677A mutation is associated with increased homocysteine levels, which are linked to a higher risk of Alzheimer's disease. This genetic variant highlights the potential impact of folate metabolism on neurodegenerative conditions in this specific population.

The article provides a comprehensive overview of the role of the endogenous detoxification system in the pathogenesis of age-related neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). It highlights epidemiological evidence linking environmental toxicant exposure to the onset and progression of these diseases, and discusses how dysfunction of detoxification pathways, including enzymes and transporters, can exacerbate neurodegenerative processes. The article also explores the potential of targeting nuclear receptor signaling pathways, such as the pregnane X receptor (PXR), as a promising therapeutic strategy to restore detoxification capacity and modify disease trajectories.

The article provides a comprehensive overview of the Keystone Symposia conference on Myeloid Cell Diversity, highlighting key presentations on topics such as phagocytosis of dead cells, neutrophil behavior, myeloid cell states, and the impact of lifestyle factors on myeloid cells in disease states. It also discusses the role of myeloid cells in Alzheimer's disease, specifically how their dissociation may mediate vascular dysfunction.

This study demonstrated that physical exercise pretreatment improves recognition memory and enhances structural synaptic plasticity in the hippocampus of Alzheimer’s disease (AD) rats, primarily through the activation of hippocampal TREM2. Blocking TREM2 diminished these neuroprotective effects, indicating that exercise mitigates synaptic injury and cognitive decline in AD via a TREM2-dependent mechanism.

Neurocognitive dysfunction is common in heart failure (HF), and is independently associated with worse outcomes including mortality, rehospitalization, and reduced quality of life. It is paramount to raise awareness of the neurocognitive consequences in ischemic HF and devise strategies for recognition and prevention as an important target of patient management and personalized decision making that contributes to patient outcomes. This review outlines the current evidence and gaps in our understanding of neurocognitive dysfunction in HF and their implications on selection of revascularization strategies in patients with ischemic HFrEF.

This study demonstrates that the Psychological Telephone Triage System (PTT) is an effective and cost-efficient method for early identification of patients with urgent cognitive impairment, particularly in the context of Alzheimer’s disease (AD), helping to reduce unnecessary on-site visits and healthcare burden. The findings suggest that implementing this interdisciplinary pre-screening and triage process can improve management of the rising demand for dementia assessments, especially with new therapeutic options and increasing prevalence of dementia globally.

This systematic review examined the relationship between cognition and motor speech production in healthy older adults and those with mild cognitive impairment, analyzing 22 studies with 747 participants. Findings suggest that cognitive functions, particularly attention and executive abilities, are linked to motor speech performance, though evidence quality varies and gaps remain.

The article discusses the potential of glucagon-like peptide-1 (GLP-1) receptor agonists (GRA) as novel therapeutic agents for neurodegenerative diseases (NDs) like Alzheimer's disease (AD) and Parkinson's disease (PD). GRA have shown promising effects in modulating neuroinflammation, oxidative stress, mitochondrial and autophagic functions, and protein misfolding in preclinical studies. Clinical trials have demonstrated that GRA like exenatide, liraglutide, and lixisenatide can improve motor deficits in PD and cognitive function in AD patients.

The article discusses the role of microglial activation in Alzheimer's disease (AD), highlighting its impact on neuroinflammation and cognitive dysfunction. It explores the molecular mechanisms underlying microglial activation, potential therapeutic targets, and updates on clinical trials for drugs aimed at mitigating neuroinflammation and cognitive decline in AD.